Semaglutide: GLP-1 receptor agonist research overview

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk that has become one of the most extensively studied compounds in metabolic research over the past decade. First approved by the FDA in 2017 under the trade name Ozempic for type 2 diabetes management, and subsequently approved as Wegovy in 2021 for chronic weight management, semaglutide has been the subject of multiple large phase 3 clinical programs encompassing tens of thousands of participants. Its once-weekly subcutaneous dosing schedule, long plasma half-life, and robust clinical effect sizes across cardiometabolic endpoints have distinguished it within the GLP-1 class and generated substantial interest in its underlying biology.

What is semaglutide?

Semaglutide is a 31-amino acid polypeptide analogue of the endogenous incretin hormone GLP-1, sharing approximately 94% amino acid sequence homology with native human GLP-1(7-37). Its molecular weight is 4,113.58 Da. The compound was engineered by Novo Nordisk through two key structural modifications designed to resist proteolytic degradation and extend circulating half-life. First, the alanine at position 8 is replaced by 2-aminoisobutyric acid (Aib), protecting the N-terminus from dipeptidyl peptidase-4 (DPP-4)-mediated cleavage. Second, a C18 fatty diacid chain is attached via a linker to lysine at position 26, enabling reversible binding to serum albumin and dramatically slowing renal clearance.

Semaglutide received its first FDA approval in December 2017 (Ozempic, 0.5 mg and 1 mg weekly) for glycemic control in adults with type 2 diabetes. A higher-dose formulation (2.4 mg weekly, Wegovy) was approved in June 2021 for chronic weight management. An oral formulation (Rybelsus, 7 mg and 14 mg daily) was approved in September 2019, making semaglutide the first oral GLP-1 receptor agonist to reach the US market. Regulatory approvals have subsequently been granted in the European Union, United Kingdom, Canada, Australia, and Japan across multiple indications. For research purposes outside approved clinical settings, semaglutide is classified as a research-use compound in most jurisdictions and is not approved for self-administration.

Mechanism of action

Semaglutide exerts its effects by selectively binding to and activating the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed on pancreatic beta cells, the gastrointestinal tract, the hypothalamus, the brainstem, the heart, the kidneys, and peripheral tissues. Upon binding, semaglutide stimulates adenylate cyclase, raising intracellular cyclic AMP (cAMP) levels and activating protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC2) pathways. In pancreatic beta cells this cascade produces glucose-dependent potentiation of insulin secretion — a mechanism that sharply limits hypoglycemia risk because the insulinotropic effect diminishes as plasma glucose falls toward euglycemia.

Simultaneously, GLP-1R activation on pancreatic alpha cells suppresses inappropriate glucagon secretion in a glucose-dependent manner, further lowering postprandial hepatic glucose output. Beyond the pancreas, central GLP-1R signaling in the hypothalamus (arcuate and paraventricular nuclei) and brainstem (area postrema and nucleus tractus solitarius) reduces appetite and energy intake. Gastric emptying is modestly delayed, particularly in the early postprandial window, attenuating postmeal glucose excursions. Semaglutide also engages GLP-1 receptors on cardiac myocytes and endothelial cells; preclinical and clinical data suggest direct cardioprotective effects independent of weight loss, though mechanisms remain an active area of research (see citations).

What the research shows

Semaglutide has been evaluated across multiple large-scale clinical programs. The SUSTAIN program (SUSTAIN 1–10) assessed subcutaneous semaglutide (0.5 mg and 1 mg weekly) in type 2 diabetes populations and demonstrated reductions in HbA1c of 1.1–1.8 percentage points versus comparators, with consistent body weight reduction. The PIONEER program evaluated oral semaglutide across similar endpoints. The pivotal cardiovascular outcomes trial, SUSTAIN 6 (NCT01720446), enrolled 3,297 participants with type 2 diabetes at high cardiovascular risk; it demonstrated non-inferiority for major adverse cardiovascular events (MACE) and a nominally significant 26% reduction in MACE (see citations).

The STEP (Semaglutide Treatment Effect in People with Obesity) program evaluated 2.4 mg weekly subcutaneous semaglutide across four phase 3 trials. STEP 1 (NCT03548935), published in the New England Journal of Medicine in 2021 by Wilding et al. (PMID 33567185), enrolled 1,961 adults without diabetes and reported a mean 14.9% body weight reduction with semaglutide versus 2.4% with placebo at 68 weeks (see citations). STEP 2 enrolled adults with type 2 diabetes; STEP 3 added intensive behavioral intervention; STEP 4 demonstrated the effects of discontinuation, showing weight regain after cessation.

The SELECT trial (NCT03574597), published in 2023 by Lincoff et al. (PMID 37952131), was a landmark cardiovascular outcomes trial enrolling 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes. Over a mean follow-up of approximately 40 months, semaglutide 2.4 mg weekly reduced MACE (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 20% versus placebo (HR 0.80, 95% CI 0.72–0.90; p<0.001) (see citations). This was the first dedicated cardiovascular outcomes trial in a non-diabetic obesity population to show a significant reduction in hard cardiovascular endpoints with a GLP-1 receptor agonist, broadening the research interest in this compound substantially.

Pharmacokinetics

Semaglutide exhibits a plasma half-life of approximately 7 days (165–184 hours), which enables once-weekly subcutaneous dosing and is the defining pharmacokinetic feature distinguishing it from earlier GLP-1 agonists such as exenatide (half-life ~2.4 hours) and liraglutide (half-life ~13 hours). The prolonged half-life results primarily from reversible albumin binding mediated by the C18 fatty diacid side chain, which reduces both renal filtration and receptor-mediated clearance.

Following subcutaneous injection, peak plasma concentration (Cmax) is reached within 1 to 3 days post-dose, and absolute bioavailability by the subcutaneous route is approximately 89%. Steady-state exposure is achieved after 4–5 weeks of once-weekly dosing. Semaglutide is metabolized via non-specific proteolytic cleavage of the peptide backbone by serum and tissue proteases and through sequential beta-oxidation of the fatty acid linker. It is not a substrate for CYP450 enzymes, so drug-drug interactions via that pathway are not a concern. Excretion of metabolites occurs in both urine and feces. Oral semaglutide (Rybelsus) has an absolute bioavailability of approximately 1% in fasted conditions, necessitating a 300 mg SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) absorption enhancer in each tablet.

Common research dose ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Published phase 3 clinical literature reports a subcutaneous dose range of 0.25 mg to 2.4 mg once weekly for semaglutide. The STEP 1 trial (Wilding et al., PMID 33567185) and the SELECT trial (Lincoff et al., PMID 37952131) both employed an escalation schedule beginning at 0.25 mg once weekly, doubling every 4 weeks through 0.5 mg and 1.0 mg, then escalating to 1.7 mg and finally to the 2.4 mg maintenance dose over approximately 16 weeks. The 0.25 mg starting dose is described in the literature as an initiation dose to improve tolerability and is not intended as a therapeutic maintenance level. The escalation schedule reported in SUSTAIN trials for type 2 diabetes management used a lower maintenance ceiling of 0.5 mg or 1.0 mg weekly (see citations).

Literature reports once-weekly subcutaneous dosing with escalation from 0.25 mg to a 2.4 mg maintenance level over approximately 16 weeks. The ClinicalTrials.gov registry entry for STEP 1 (NCT03548935) documents the full escalation regimen. Researchers studying this compound should consult the published protocols and the FDA prescribing information for the approved formulations, as experimental designs outside approved indications require institutional review and appropriate regulatory approvals.

Storage and handling

Lyophilized semaglutide peptide is stored at −20 °C in a sealed, dessicant-protected vial. Once reconstituted, solutions should be maintained at 2–8 °C (standard refrigerator temperature) and used within 28 days. Reconstituted solutions should not be frozen. As with all lyophilized peptides, exposure to repeated freeze-thaw cycles, prolonged ambient temperature, and direct light should be avoided. These storage parameters are consistent with those reported for research-grade semaglutide peptide across vendor certificates of analysis and align with the general stability characteristics described in the FDA-approved Ozempic and Wegovy prescribing information, which specify refrigerated storage and a 28-day in-use window at room temperature for the pre-filled pen.

What semaglutide is NOT

Semaglutide is often grouped with or confused against several related compounds. It is not tirzepatide: tirzepatide is a dual GIP/GLP-1 receptor agonist (a 'twincretin') with a structurally distinct 39-amino acid backbone based on the GIP sequence rather than GLP-1, and it engages the GIP receptor with native affinity in addition to the GLP-1 receptor. It is not retatrutide, which is a triple agonist at GIP, GLP-1, and glucagon receptors simultaneously. It is not liraglutide, an earlier once-daily GLP-1 agonist with a C16 fatty acid acylation and a much shorter half-life of approximately 13 hours. It is not exenatide or dulaglutide, which are structurally distinct exendin-4-based GLP-1 agonists. Researchers should carefully verify sequence, molecular weight (4,113.58 Da for semaglutide), and purity documentation when sourcing the compound, as vendor naming conventions in the research market are not standardized.

References

The citations below represent the primary peer-reviewed and regulatory sources underlying the claims in this article. Readers seeking primary data are directed to the STEP 1 trial (Wilding et al., 2021, PMID 33567185), the SELECT cardiovascular outcomes trial (Lincoff et al., 2023, PMID 37952131), the SUSTAIN 6 cardiovascular outcomes trial, the FDA-approved prescribing information for Ozempic (NDA 209637) and Wegovy (NDA 213051), and the ClinicalTrials.gov registry for NCT03548935. For pharmacokinetic data, the FDA clinical pharmacology reviews for NDA 209637 and NDA 213051 provide the most detailed publicly available information on absorption, distribution, metabolism, and excretion.